Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus interventional and targeted therapy for unresectable hepatocellular carcinoma
ChiCTR2400091083Phase 4Not yet recruiting
- Sponsor
- Shenyang Sixth People's Hospital
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in hepatocellular carcinoma (HCC), sponsored by Shenyang Sixth People's Hospital. Primary endpoint: Objective response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400091083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091083.